EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients

Cinthya Yareli Anguiano Serrato, Fabiola Solorzano-Ibarra iD, Ignacio Mariscal-Ramirez, Maria Iyali Torres-Bustamante, Sylvia Elena Totsuka-Sutto, Jorge Raúl Vázquez-Urrutia, Aldo Alcaraz-Wong, Betsabé Contreras-Haro, Pablo Cesar Ortiz-Lazareno

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27041634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Cinthya Yareli Anguiano Serrato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital General Regional N°2 El Marqués, Instituto Mexicano del Seguro Social, Querétaro 76246, Querétaro, Mexico. Hauptthemen laut MEDLINE: Killer Cells, Natural, Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Guadalajara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant systemic therapy (NST) is standard for locally advanced breast cancer (BC), yet predictors of pathological complete response (pCR) remain elusive. While Natural Killer (NK) cells are vital for anti-tumor response, their specific receptor dynamics during NST are poorly defined. This study provides a high-dimensional characterization of the peripheral NK cell landscape and immune signatures associated with therapeutic success. This prospective cohort study included 34 BC patients and 35 healthy donors (HD). Clinical characteristics were collected, and peripheral blood NK cell subsets were evaluated. We utilized high-parameter flow cytometry and unsupervised clustering (UMAP) to longitudinally track NK cell phenotypes (NKG2D, DNAM-1, PD-1, TIGIT) pre- and post-NST. NK cell cytotoxicity was evaluated, and serum levels of related IL-17A (interleukin), IL-2, IL-4, IL-10, IL-6, TNF-α (tumor necrosis factor-alpha), Fas, sFasL, IFN-γ (interferon-gamma), and Granzyme A were analyzed. Patients exhibited distinct NK cell profiles according to the pathological response. Only 12 BC patients achieved pCR. These patients showed improved NK cell cytotoxicity and higher concentrations of IL-2, TNF-α, sFASL, and Granzyme B after treatment compared with Non-pCR patients. In contrast, in Non-pCR patients, the percentages of CD56bright NK cells increased after neoadjuvant therapy, whereas the more cytotoxic CD56dim NK cell population decreased. Additionally, NK cells from Non-pCR patients exhibited higher co-expression of inhibitory checkpoints (TIGIT and PD-1), indicating reduced NK cell function. Otherwise, pCR patients displayed a more favorable balance of activating receptors (NKG2D and DNAM-1), and a favorable shift in the TIGIT/DNAM-1 activating-to-inhibitory axis. This study highlights the potential role of NK cells in determining the response to neoadjuvant therapy in BC patients. Those who achieved pCR showed enhanced NK cell activity and higher expression of activating receptors. Moreover, NK cells from Non-pCR patients showed lower cytotoxicity and higher expression of inhibitory receptors. These results suggest that NK cell phenotype evaluation could serve as a biomarker of treatment response in patients with BC. They also showed that the TIGIT/DNAM-1 axis can be a critical determinant of pCR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalBreast NeoplasmsNeoadjuvant TherapyHumansFemaleMiddle AgedAdultReceptors, ImmunologicPhenotypeProgrammed Cell Death 1 ReceptorPathologic Complete ResponseT Lineage-Specific Activation Antigen 1NK Cell Lectin-Like Receptor Subfamily KCytokinesProspective StudiesTreatment OutcomeAntigens, Differentiation, T-LymphocyteAged

Stichwörter der Autor:innen

DNAM-1NK cellsNKG2DNon-pCRPD-1TIGITTIGIT/DNAM-1 axisbreast cancercytokinescytotoxicityhigh-dimensional flow cytometryimmune checkpointsneoadjuvant therapypCR

Substanzen

Receptors, ImmunologicProgrammed Cell Death 1 ReceptorT Lineage-Specific Activation Antigen 1NK Cell Lectin-Like Receptor Subfamily KCytokinesTIGIT protein, humanKLRK1 protein, humanPDCD1 protein, humanAntigens, Differentiation, T-Lymphocyte

Autor:innen und Institutionen

  • Hospital General Regional N°2 El Marqués, Instituto Mexicano del Seguro Social, Querétaro 76246, Querétaro, Mexico.
  • Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico-Degenerativas, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisc…
  • Unidad Médica de Alta Especialidad, Departamento de Oncología Médica, Hospital de Especialidades (UMAE, HE), Centro Médico Nacional de Occidente Ignacio García Téllez, IMSS, Guadalajara 44340, Jalisco, Mexico.
  • Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
  • Department of Medicine, The Pennsylvania State University College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA.
  • Unidad Médica de Alta Especialidad, Departamento de Patología, Hospital de Especialidades (UMAE, HE), Centro Médico Nacional de Occidente Ignacio García Téllez, IMSS, Guadalajara 44340, Jalisco, Mexico.

ORCID-Profile: Fabiola Solorzano-Ibarra

Förderung

  • Universidad de Guadalajara

Zitieren

APA

Anguiano Serrato, C. Y., Solorzano-Ibarra, F., Mariscal-Ramirez, I., Torres-Bustamante, M. I., Totsuka-Sutto, S. E., Vázquez-Urrutia, J. R., Alcaraz-Wong, A., Contreras-Haro, B., & Ortiz-Lazareno, P. C. (2026). Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041634

Vancouver

Anguiano Serrato CY, Solorzano-Ibarra F, Mariscal-Ramirez I, Torres-Bustamante MI, Totsuka-Sutto SE, Vázquez-Urrutia JR, et al. Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041634

BibTeX
@article{AnguianoSerrato2026,
  author = {Anguiano Serrato, Cinthya Yareli and Solorzano-Ibarra, Fabiola and Mariscal-Ramirez, Ignacio and Torres-Bustamante, Maria Iyali and Totsuka-Sutto, Sylvia Elena and Vázquez-Urrutia, Jorge Raúl and Alcaraz-Wong, Aldo and Contreras-Haro, Betsabé and Ortiz-Lazareno, Pablo Cesar},
  title = {Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27041634}
}
Kostenlos starten →